[MOL] A phase-1 for INGN241 [00026] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] A phase-1 for INGN241

Introgen Therapeutics of Austin announced that it will begin a
phase-1 trial of INGN241 (Adenoviral-mda7) for solid tumors. The
company expects to enroll 15  patients in a dose-escalating trial of
this adenovirus that targets the mda-7 tumor-suppressor gene. In
preclinical studies the agent suppressed the growth of various types
of cancer cells, according to the company.
We invite you to take a look at our Album.                                               
  ( Very informational, good tips, Molers pictures, art work and much more....